CYP27B1 and neoplasm: Our previous study showed reduced CYP27B1 levels in primary and metastatic ovarian cancers compared normal controls, with the strongest reduction found in cancers showing a high proliferation index, lack of immune response, presence of necrosis, and dynamic tumor growth.